Excited to share our new paper out today in @NatureMetabolism! "Hyperglycosylation is a metabolic driver of Alzheimer’s disease" *We bridged spatial metabolomics (MALDI-MSI glycomics + lipidomics + isotopic pulse-chase tracing) directly to experimental biochemistry (genetic knockdown of glycan enzymes + glucosamine supplementation in AD models) and real-world public health data (EHR analysis showing glucosamine use linked to faster MCI-to-AD progression and worse survival). **Key takeaway: The AD brain shows conserved hyperglycosylation driven by ramped-up glycan biosynthesis — not just a byproduct, but a causal driver. Reducing it helps cognition; boosting it (e.g., via glucosamine) worsens outcomes. ***We applied cutting-edge spatial tech to functional validation and clinical translation. Full open-access paper: nature.com/articles/s42255-0… Huge thanks to the incredible team, collaborators (incl. Matt Gentry, Stefan Prokop, @ji0ngbi0n , Yi Guo, @lichenbiostat, Ralph Deberardinis & others), and the patients/families who make this work possible.